FDA Imposes Partial Clinical Hold on Pepgen's Key FREEDOM2 Trial Over Preclinical Concerns
PEPG has more than doubled off its 52-week low of $0.88.
Summary
The U.S. FDA has placed a partial clinical hold on Pepgen Inc.'s FREEDOM2 trial, citing concerns related to preclinical pharmacology and toxicology. This is a significant negative development for the company, as a clinical hold on a key trial introduces substantial uncertainty regarding the drug's development timeline and potential safety profile. While Pepgen reiterated its guidance for reporting data from certain cohorts in Q1 and 2H 2026 and secured regulatory clearance to initiate the trial in South Korea, Australia, and New Zealand, the U.S. FDA's action is paramount. Traders will closely monitor the company's response to the FDA's concerns and the potential impact on the trial's progression in the critical U.S. market.
At the time of this announcement, PEPG was trading at $4.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $0.88 to $7.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.